REDHILL BIOPHARMA LTD-SP ADR (RDHL) Fundamental Analysis & Valuation

NASDAQ:RDHL • US7574683014

Current stock price

0.875 USD
+0.02 (+2.6%)
At close:
0.875 USD
0 (0%)
After Hours:

This RDHL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RDHL Profitability Analysis

1.1 Basic Checks

  • In the past year RDHL has reported negative net income.
  • In the past year RDHL has reported a negative cash flow from operations.
  • In the past 5 years RDHL reported 4 times negative net income.
  • In the past 5 years RDHL always reported negative operating cash flow.
RDHL Yearly Net Income VS EBIT VS OCF VS FCFRDHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

  • RDHL has a worse Return On Assets (-45.00%) than 61.98% of its industry peers.
Industry RankSector Rank
ROA -45%
ROE N/A
ROIC N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RDHL Yearly ROA, ROE, ROICRDHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

  • With a decent Gross Margin value of 60.31%, RDHL is doing good in the industry, outperforming 69.79% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RDHL has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for RDHL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
RDHL Yearly Profit, Operating, Gross MarginsRDHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. RDHL Health Analysis

2.1 Basic Checks

  • RDHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RDHL has more shares outstanding
  • RDHL has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, RDHL has an improved debt to assets ratio.
RDHL Yearly Shares OutstandingRDHL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
RDHL Yearly Total Debt VS Total AssetsRDHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -34.56, we must say that RDHL is in the distress zone and has some risk of bankruptcy.
  • RDHL has a Altman-Z score of -34.56. This is amonst the worse of the industry: RDHL underperforms 89.06% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -34.56
ROIC/WACCN/A
WACC8.86%
RDHL Yearly LT Debt VS Equity VS FCFRDHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

  • A Current Ratio of 0.56 indicates that RDHL may have some problems paying its short term obligations.
  • With a Current ratio value of 0.56, RDHL is not doing good in the industry: 89.58% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.42 indicates that RDHL may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.42, RDHL is not doing good in the industry: 88.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.42
RDHL Yearly Current Assets VS Current LiabilitesRDHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RDHL Growth Analysis

3.1 Past

  • RDHL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.30%.
  • RDHL shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.17%.
  • Measured over the past years, RDHL shows a small growth in Revenue. The Revenue has been growing by 5.04% on average per year.
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%58.59%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue is expected to grow by 45.22% on average over the next years. This is a very strong growth
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RDHL Yearly Revenue VS EstimatesRDHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
RDHL Yearly EPS VS EstimatesRDHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K -2.5K

More info and screens

Find the best growth stocksShow best growing peers

0

4. RDHL Valuation Analysis

4.1 Price/Earnings Ratio

  • RDHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RDHL Price Earnings VS Forward Price EarningsRDHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RDHL Per share dataRDHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RDHL Dividend Analysis

5.1 Amount

  • No dividends for RDHL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RDHL Fundamentals: All Metrics, Ratios and Statistics

REDHILL BIOPHARMA LTD-SP ADR

NASDAQ:RDHL (3/17/2026, 6:54:11 PM)

After market: 0.875 0 (0%)

0.875

+0.02 (+2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16
Earnings (Next)N/A
Inst Owners9.77%
Inst Owner Change2017.77%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.47M
Revenue(TTM)8.04M
Net Income(TTM)-8.27M
Analysts82.86
Price TargetN/A
Short Float %224.08%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.47
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS1.57
BVpS-0.86
TBVpS-1.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.31%
FCFM N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
F-Score4
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.25%
Cap/Sales 0.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.42
Altman-Z -34.56
F-Score4
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)1.49%
Cap/Depr(5y)123.93%
Cap/Sales(3y)0.2%
Cap/Sales(5y)16.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%58.59%
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A
EBIT growth 1Y-215.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y68.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.74%
OCF growth 3YN/A
OCF growth 5YN/A

REDHILL BIOPHARMA LTD-SP ADR / RDHL Fundamental Analysis FAQ

What is the fundamental rating for RDHL stock?

ChartMill assigns a fundamental rating of 1 / 10 to RDHL.


What is the valuation status of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?

ChartMill assigns a valuation rating of 0 / 10 to REDHILL BIOPHARMA LTD-SP ADR (RDHL). This can be considered as Overvalued.


How profitable is REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?

REDHILL BIOPHARMA LTD-SP ADR (RDHL) has a profitability rating of 1 / 10.


What is the financial health of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?

The financial health rating of REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 0 / 10.